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Surgical patients are at high risk for developing infectious complications and postoperative
delirium. Prolonged infections and delirium result in worse outcome. Granulocyte-macro-
phage colony-stimulating factor (GM-CSF) and influenza vaccination are known to increase
HLA-DR on monocytes and improve immune reactivity. This study aimed to investigate
whether GM-CSF or vaccination reverses monocyte deactivation. Secondary aims were
whether it decreases infection and delirium days after esophageal or pancreatic resection
over time.
Methods
In this prospective, randomized, placebo-controlled, double-blind, double dummy trial set-
ting on an interdisciplinary ICU of a university hospital 61 patients with immunosuppression
(monocytic HLA-DR [mHLA-DR] <10,000 monoclonal antibodies [mAb] per cell) on the first
day after esophageal or pancreatic resection were treated with either GM-CSF (250 μg/m2/
d), influenza vaccination (Mutagrip 0.5 ml/d) or placebo for a maximum of 3 consecutive
days if mHLA-DR remained below 10,000 mAb per cell. HLA-DR on monocytes was mea-
sured daily until day 5 after surgery. Infections and delirium were followed up for 9 days
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after surgery. Primary outcome was HLA-DR on monocytes, and secondary outcomes were
duration of infection and delirium.
Results
mHLA-DR was significantly increased compared to placebo (p < 0.001) and influenza vacci-
nation (p < 0.001) on the second postoperative day. Compared with placebo, GM-CSF-
treated patients revealed shorter duration of infection (p < 0.001); the duration of delirium
was increased after vaccination (p = 0.003).
Conclusion
Treatment with GM-CSF in patients with postoperative immune suppression was safe and
effective in restoring monocytic immune competence. Furthermore, therapy with GM-CSF
reduced duration of infection in immune compromised patients. However, influenza vacci-




Postoperative infections and delirium occur in up to 50% of high-risk patients undergoing
high-risk surgery requiring intensive care unit (ICU) and prolonged hospital stay [1–6]. Surgi-
cal inflammatory stress can cause delirium and immune suppression [7–10]. Postoperative
immune suppression increases the risk for infections and delirium [11–13].
Immune suppression can be measured by a decreased level of human monocyte leukocyte
antigen-DR receptor (mHLA-DR) expression on monocytes [12], a hallmark of monocyte
deactivation associated with impaired innate and adaptive immune responses [14, 15]. Pro-
longed downregulation of mHLA-DR has been associated with worse outcomes such as infec-
tious complications, severe sepsis and increased mortality in ICU patients [16–19].
Several studies have demonstrated that suppressed mHLA-DR could be restored by admin-
istration of vaccination or Granulocyte-Macrophage Colony-stimulating factor (GM-CSF)
[20–27]. Our research group found an increase in mHLA-DR after influenza vaccination in
patients with untreated cancer of the upper aero-digestive tract [23] and after preoperative vac-
cination [28]. Others found the normalization of the immunoregulatory index and the stimula-
tion of the phagocytic function in the absence of essential influence on the level of HLA-DR
+ expression [29]. GM-CSF was known to restore reduced mHLA-DR in patients after cardiac
surgery ex vivo [25] as well as in vivo in patients with sepsis [24, 26, 27]. However, whether
GM-CSF or vaccination restore HLA-DR after major surgery in immunosuppressed patients is
not known.
The primary aim of the study was to investigate the effect of postoperative treatment with
GM-CSF or influenza vaccination on mHLA-DR expression. Secondary endpoints were the
number of infection and delirium days.
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Materials and Methods
Study Participants and Design
The first patient was enrolled on October 26, 2008. However, due to technical issues including
the payment process, the first acceptance of the corresponding ISRCTN application was
delayed (December 05, 2008). As a consequence 4 patients were included in the study before
acceptance of the trial registration. The authors confirm that all ongoing and related trials for
this drug/intervention are registered.
Patients with immune suppression on day 1 after esophageal or pancreatic resection (pod1)
were included in this prospective, randomized, placebo-controlled, double-blind, double
dummy trial. Immune suppression was defined as reduced mHLA-DR levels of less than
10,000 monoclonal antibodies (mAb) per cell [12]. Patient enrollment was from October 2008
to April 2011. Patients were included if they were scheduled for elective esophageal or pancre-
atic surgery and had a mHLA-DR expression  10,000 antibodies per cell on pod1. Exclusion
criteria were acquired or congenital blood cell disease, leukemia, autoimmune diseases, aller-
gies to GM-CSF or the influenza vaccine, chemotherapy or radiotherapy within the last 28
days, proven infection within the last 7 days, infection with HIV or hepatitis B or C, pharmaco-
logical immune suppression within the last 4 weeks, unstable angina pectoris, untreated
arrhythmia, thromboembolic events, cachexia, thrombocytopenia ( 100,000 /μl), neutropenia
( 1,500 /μl), anemia (hemoglobin 8 g/dl), hyperbilirubinemia (> 2 g/dl), creatinine> 1.5
g/dl, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 90 U/I, preg-
nancy or lactation, or participation in a German Drug Law (AMG) one month before and dur-
ing the study.
A total of 319 patients scheduled for esophageal or pancreatic surgery were screened. Of
these, 235 did not fulfil inclusion criteria or refused to participate and 84 patients gave their
written informed consent to participate. Of the 84 patients who consented, 21 patients had to
be excluded for the following reasons: 18 patients were not immune suppressed after surgery, 1
patient’s operation was cancelled, in 1 patient pancreatic resection was not performed and 1
patient had abnormal preoperative laboratory values which were not available preoperatively
and therefore delayed after surgery. The remaining 63 patients were immune suppressed and
were randomized according to the study protocol. Two of the patients were excluded (major
protocol violations) after randomization because one patient was inadvertently unblinded (pla-
cebo group) and one patient died of multiorgan failure after receiving study medication for
12.5 h (GM-CSF group, no causal relation to the study drug). Three additional patients were
randomized due to these two dropouts of the initially planned 60 patients. Finally, 61 patients
were included in data analysis (Fig 1). There were 23 minor protocol violations of inclusion cri-
teria and 1 minor protocol violation regarding termination of the study medication.
The study was approved by the Ethics Committee of the Landesamt für Gesundheit und
Soziales Berlin (LaGeSo), Germany (ref ZSEK15287/08) on September 01, 2008. This clinical
trial meets the requirements set out by the ICH-GCP, Declaration of Helsinki and the German
Drug Law (AMG). Written informed consent was obtained from patients.
Randomization and Treatment with Study Drugs
For blinding, consecutively numbered (randomization numbers) closed envelopes were used,
which contained the assignment to the therapy. In case of adverse reactions, severe deteriora-
tion of patient’s state or other unforeseen events the patient and/or the physician had to be
unblinded. A list with the randomization numbers and instructions for treatment was available
only to the study statistician and the local pharmacy. The medications were prepared by an
HLA-DR, Infection and Delirium Days after GM-CSF or Vaccination
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independent medically qualified person, who covered all medications for blinding. This person
was otherwise not involved in this study.
GM-CSF was administered intravenously (i.v.) and vaccination subcutaneously (s.c.). To
avoid bias, we applied a “double dummy” design: after inclusion patients were randomized in
permutated blocks of six to receive either GM-CSF i.v. and 0.9% sodium chloride (NaCl) s.c.,
vaccination with the haemagglutinin antigens of the influenza virus s.c. and NaCl i.v. or pla-
cebo (NaCl i.v. and NaCl s.c.). Starting on pod1, study drugs were administered as follows:
• GM-CSF group: 1 s.c. syringe with 0.5 ml of 0.9% NaCl and 1 perfusor syringe with 24 ml of
sargramostim (Leukine, Bayer Health Care, LLC. Seattle, WA 98101, USA) 250 μg/m2 body
surface in 0.9% NaCl (1 ml/h i.v.)
• Vaccine group: 1 s.c. syringe with 0.5 ml of influenza vaccine (Mutagrip 2009/2010, Sanofi
Pasteur MSD GmbH, Leimen, Germany), 1 perfusor syringe with 24 ml of 0.9% NaCl (1 ml/
h i.v.)
• Placebo group: 1 s.c. syringe with 0.5 ml of 0.9% NaCl, 1 perfusor syringe with 24 ml of 0.9%
NaCl (1 ml/h i.v.)
Fig 1. Consort diagram. dBs, day before surgery. dOs, day of surgery. pod, postoperative day.
doi:10.1371/journal.pone.0144003.g001
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All patients were treated with the study medication for 24 hours. If mHLA-DR levels
remained below 10,000 mAb per cell on day 2 and day 3 (pod2 and pod3) after surgery, admin-
istration of the study drugs was continued for a maximum of 72 hours (Fig 2).
Physicians in charge were unaware of group assignments and provided treatment without
interference by the researchers. All patients received standard perioperative treatment accord-
ing to our standard operating procedures [30].
Flow Cytometry and Measurement of Soluble Mediators
Blood samples were drawn daily starting on the day of surgery (dOs) until day 5 after surgery
(pod5) for measurement of mHLA-DR expression, leukocytes, C-reactive protein (CRP), pro-
calcitonin (PCT) and interleukin 6 (IL-6).
For detailed information see (S1 Methods).
Clinical Outcome Parameters
During the follow-up period until day 9 after surgery (pod9), we measured infections according
to CDC and ATS for pneumonia [31, 32], incidence of delirium using the Delirium Detection
Score (DDS, [6]) with a DDS> 3, hospital and ICU stay and disease severity using the follow-
ing scores: Acute Physiology and Chronic Health Evaluation II (APACHE-II), Sequential
Organ Failure Assessment (SOFA), Simplified Acute Physiology Score-II (SAPS-II) and Thera-
peutic Intervention Scoring System (TISS)-28. All adverse and serious adverse events that
occurred within 9 days after surgery were followed up until day 30 after surgery (Fig 2).
Statistical Analysis
Data were summarized using arithmetic mean ± standard deviation (SD), median [25%, 75%
quartiles], or frequency [%], as appropriate. Since this was an exploratory pilot study, sample
size calculations were not performed. Due to the distribution of the data, tests were performed
using non-parametric methods.
For the primary endpoint mHLA-DR, infection duration, and delirium duration, differences
among treatment groups on the first and second postoperative days (pod1 and pod2) were
assessed using the Kruskal-Wallis test followed by pairwise comparisons using the Mann-
Whitney test. Differences within treatment groups between pod1 and pod2 (pre and post treat-
ment) were assessed using the paired Wilcoxon test. Basic patient characteristics and post
intervention characteristics were evaluated for group differences using the Kruskal-Wallis test
for continuous variates and the Fisher exact test for categorical variates.
All tests were two-tailed. Statistical significance was declared at the 0.05 level. Since this is
an exploratory analysis, no adjustments for multiple testing were carried out. All calculations
were performed with IBM SPSS Statistics, Version 19, and SAS (Version 9.1) software.
Results
Study Population and Study Groups
Basic patient characteristics did not differ between groups except for gender (p = 0.045)
(Table 1). In the GM-CSF group, study medication was given to all patients on pod1, to 1
patient on pod2, and to 3 patients on pod3. In the vaccination group, study medication was
given to all patients on pod1, to 20 patients on pod2 and to 15 patients on pod3. In the placebo
group, study medication was administered in all patients on pod1 and pod2 as well as in 17
patients on pod3.
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Primary endpoint (mHLA-DR)
HLA-DR was increased compared to placebo (p< 0.001) and influenza vaccination
(p< 0.001) on pod2 (Fig 3 and Table 2). Differences between groups with respect to pre-post
(pod1 –pod2) were seen for patients who received GM-CSF compared to those who received
vaccination (p< 0.001) and placebo (p< 0.001; Table 2).
Secondary endpoints (infection and delirium, infection days and delirium
days)
Fewer infection days were seen in the GM-CSF-treated patients (p< 0.001) after surgery (Fig
4; Table 3) compared to placebo.
Fig 2. Flow diagram. dBs, day before surgery. dOs, day of surgery. pod, postoperative day. *Study drug
treatment for a maximum of 3 consecutive days (pod1 –pod3) depending on mHLA-DR expression.
doi:10.1371/journal.pone.0144003.g002
Table 1. Basic patient characteristics and pre-interventional course. Continuous quantities in median (25%-75% percentiles), frequencies with n (%);
NRS, Numeric Rating Scale; dBs, day before surgery; pod1, day 1 after surgery; ASA, American Society of Anesthesiologists; AUDIT score, Alcohol Use Dis-
orders Identification Test; PONV, postoperative nausea and vomiting; APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute
Physiology Score; SOFA, Sequential Organ Failure Assessment; TISS, Therapeutic Intervention Scoring System; ICU, Intensive Care Unit.
Placebo (n = 20) Vaccine (n = 21) GM-CSF(n = 20) p-value (all groups)
Age [years] 64 (55–74) 67 (62–72) 64 (53–70) 0.251
Gender male/female [n (%)] 11/9 (55/45) 15/6 (71/29) 18/2 (90/10) 0.045
Body Mass Index [kg/m2] 25.5 (23.6–28.3) 24.5 (21.2–29.3) 26.9 (23.2–28.1) 0.917
Pancreatic/esophageal resection [n] 9/11 13/8 10/10 0.588
ASA score II/III [n] 12/8 9/12 9/11 0.532
smoker/nonsmoker/did never smoke [n] 8/5/7 6/10/5 5/9/6 0.601
AUDIT score 3 (0–6) 1 (0–7) 3 (0–5) 0.989
Metabolic equivalent (MET) <4/4-10/>10 1/17/2 2/18/1 0/19/1 0.853
NRS at rest dBs 0 (0–3) 0 (0–0) 0 (0–2) 0.356
NRS at rest pod1 3 (1–3) 3 (0–5) 3 (0–5) 0.525
NRS during movement pod1 5 (2–8) 4.5 (3–8) 6 (3–9) 0.351
Surgical time [min] 360 (304–440) 345 (275–430) 360 (345–430) 0.508
Blood loss [ml] 625 (338–1000) 600 (400–800) 700 (500–1100) 0.616
Blood glucose [mg/dl] 131 (120–139) 140 (128–164) 137 (122–147) 0.150
Blood lactate [mmol/l] (max.) 1.44 (1.10–1.87) 1.67 (1.06–1.95) 1.72 (1.24–2.64) 0.549
Systolic blood pressure [mmHg] 115 (112–120) 122 (110–130) 115 (112–125) 0.446
PONV 2 (1.00–3.00) 1 (0.00–2.00) 1 (1.00–2.00) 0.510
APACHE II scoreon admission to ICU 16 (11–18) 14 (7–18) 12 (11–16) 0.411
SAPS II scoreon admission to ICU 27 (21–42) 25 (17–30) 28 (22–33) 0.829
SOFA scoreon admission to ICU 2.5 (0.3–5.0) 0.0 (0.0–3.0) 1.0 (0.0–4.8) 0.185
TISS 28 score on admission to ICU 32.5 (28.0–38.5) 32.0 (25.0–37.0) 32.0 (29.0–35.5) 0.876
doi:10.1371/journal.pone.0144003.t001
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During pod1 to pod9, infection was seen in 11 patients in the placebo group, in 9 patients in
the vaccine group and in 8 patients in the GM-CSF group. Pneumonia was the most frequent
type of infection (n = 18) followed by sepsis (n = 6), wound infection (n = 5), urinary tract
infection (n = 3) and other infections (n = 2). These results did not differ between groups.
Delirium days were increased after influenza vaccination compared to the other groups
(p = 0.003 and p = 0.007) after surgery (Fig 5; Table 3).
For the period of pod1 to pod9, delirium rate did not differ significantly between groups (11
patients in the placebo group, 14 patients in the vaccine group and 12 patients in the GM-CSF
group).
Leukocytes increased on pod2 after stimulation with GM-CSF and differed significantly
from placebo (p = 0.003; Fig 6). Temperature, CRP, PCT and IL-6 did not show any significant
differences between the groups.
There were no significant differences in intra- and other postoperative parameters or in
postoperative pain, postoperative nausea and vomiting or in ICU scores on admission
Fig 3. Monocytic HLA-DR (mHLA-DR) over time. Immediately before surgery (dOs) until day 5 after
surgery (pod5) between groups.
doi:10.1371/journal.pone.0144003.g003
Table 2. Monocytic HLA-DR (mHLA-DR) on day 1 (pod1) and day 2 (pod2) after surgery. PairedWilcoxon Test (pod1 versus pod2): Placebo:
p = 0.0027; Vaccination: p = 0.013; GM-CSF: p < 0.001; Overall (Kruskal-Wallis): pod1: p = 0.667; pod2: p < 0.001; pod1 –pod2: p < 0.001; IQR: Interquartile
Range.
Mean Standard deviation Median IQR p-values (Mann-Whitney)
pod1 1 vs. 2 1 vs. 3 2 vs. 3
1: Placebo 6,688 1,805 6,709 2,707 0.906 0.426
2: Vaccination 6,740 1,614 6,777 2,287 0.467
3: GM-CSF 6,306 2,272 6,080 4,062
pod2 1 vs. 2 1 vs. 3 2 vs. 3
1: Placebo 5,712 1,853 5,668 2,759 0.633 < 0.001
2: Vaccination 5,643 2,294 5,448 3,372 < 0.001
3: GM-CSF 62,566 34,975 61,257 34,021
pod1 –pod2 1 vs. 2 1 vs. 3 2 vs. 3
1: Placebo 976 1,730 1,146 3,005 0.876 < 0.001
2: Vaccination 1,097 1,748 1,278 2,828 < 0.001
3: GM-CSF -56,260 33,910 -54,649 33,541
doi:10.1371/journal.pone.0144003.t002
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(Table 1). In addition, maximum of SOFA and TISS 28 score as well as time on ventilator, ICU
and hospital length of stay did not significantly differ between the groups (Table 4).
No study drug-related serious adverse events, adverse drug-related reactions, unexpected
adverse reactions or suspected unexpected severe adverse reactions were observed. A detailed
documentation of the safety data is given in (S1 Data).
Discussion
The major finding of this study was that GM-CSF treatment after surgery in immune compro-
mised patients increased mHLA-DR expression and decreased the number of infection days
whereas influenza vaccination increased the number of delirium days after major surgery. To
the best of our knowledge, there have been no studies that investigated postoperative in vivo
biomarker-guided administration of GM-CSF or vaccination in immune compromised surgical
patients.
Fig 4. Number of infection days. From day 1 (pod1, before intervention) until day 9 after surgery (pod9).
Between all three groups: p = 0.001. Placebo vs. GM-CSF: p < 0.001. Placebo vs. vaccination: p = 0.068.
Vaccination vs. GM-CSF: p = 0.044.
doi:10.1371/journal.pone.0144003.g004
Table 3. Infection and delirium days (DDS > 3). Overall (Kruskal-Wallis): Infection days: p = 0.001;Delirium days (DDS > 3): p = 0.004; IQR: Interquartile
Range.
Mean Standard deviation Median IQR p-values (Mann-Whitney)
Duration of Infection (days) 1 vs. 2 1 vs. 3 2 vs. 3
1: Placebo 1.35 1.982 0.00 3 0.068 < 0.001
2: Vaccination 1.05 1.883 0.00 2 0.044
3: GM-CSF 0.74 1.807 0.00 0
Duration of Delirium (days) 1 vs. 2 1 vs. 3 2 vs. 3
1: Placebo 0.6222 1.1194 0.00 1 0.003 0.737
2: Vaccination 0.9788 1.3247 0.00 2 0.007
3: GM-CSF 0.5556 0.8471 0.00 1
doi:10.1371/journal.pone.0144003.t003
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Several previous studies have demonstrated that GM-CSF can improve immune responses
in immunosuppressed patients both ex vivo and in vivo. Börgermann et al. showed that
decreased mHLA-DR expression could be restored by GM-CSF ex vivo in patients undergoing
cardiopulmonary bypass [25]. The same group demonstrated that GM-CSF also increases ex
vivo endotoxin-induced monocyte cytokine release in immunosuppressed trauma patients
[33]. In recent open-label and randomized trials, we and others have shown that GM-CSF
treatment can restore innate immune responses in adult patients with severe sepsis-associated
immunosuppression and in children with multiple organ dysfunction syndrome [24, 26, 34].
In accordance with previous studies, we observed an immediate increase of mHLA-DR to pre-
operative or even supernormal levels in patients with surgery-induced immunosuppression on
Fig 5. Number of delirium days (DDS > 3). From day 1 (pod1, before intervention) until day 9 after surgery
(pod9). Between all three groups: p = 0.004. Placebo vs. GM-CSF: p = 0.737. Placebo vs. vaccination:
p = 0.003. Vaccination vs. GM-CSF: p = 0.007.
doi:10.1371/journal.pone.0144003.g005
Fig 6. Leukocytes over time. From day of surgery (dOs) until day 5 after surgery (pod5) between groups.
Leukocytes significantly increased on pod2 (p = 0.003) after stimulation with GM-CSF.
doi:10.1371/journal.pone.0144003.g006
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the 1st day after administration of GM-CSF. This increase most likely relies on an induction of
key molecules in the class II MHC pathway of monocytes [35]. However, mHLA-DR levels
rapidly decreased when GM-CSF treatment was discontinued which is likely due to the short
half-life of GM-CSF and replacement of circulating monocytes from the bone marrow pool.
Noteworthy, on the fifth day after surgery it decreased to levels comparable to the placebo
group (mHLA-DR was over 10,000 mAb/cell but still depressed compared to preoperative lev-
els). GM-CSF treatment also increased the postoperative leukocyte counts while other markers
of inflammation and infection such as temperature, CRP, PCT and IL-6 remained unaffected.
These data are in accordance with previous studies, which showed no effect of GM-CSF treat-
ment on the infection parameters PCT and IL-6 in critically ill patients [24, 26, 34].
Recent studies suggested that influenza vaccination could also increase suppressed
mHLA-DR expression. Haining et al. demonstrated increased mHLA-DR expression after
influenza vaccination in children after hematopoietic stem cell transplantation [20]. We
showed similar effects in patients with upper aerodigestive tract cancer [23]. In contrast, in the
same study influenza vaccination failed to significantly prevent downregulation of mHLA-DR
expression when the vaccine was administered pre-operatively [23]. Thus, in conjunction with
the current study demonstrating no beneficial effect of post-operative influenza vaccination in
immunosuppressed surgical patients, vaccination at least with influenza vaccine did not appear
to be an effective immunostimulatory treatment approach either to prevent or to reverse sur-
gery-induced immunosuppression. After influenza vaccination, healthy volunteers showed a
significant increase in the frequency of H1N1-specific IL-4+CD4+ T cells after vaccination.
However, healthy volunteers also showed an increase in IFN-γ+CD4+ T cells after vaccination
despite the fact that no significant changes in HLA-DR- and CD86 expression from before to
after vaccination were observed. In addition, the cytokine profile after administration of vac-
cine showed that healthy controls had significantly greater levels of fractalkine, IFN-γ, MCP-3,
interleukin 1β, interleukin 6, and MIP-1α [36] i.e. they had a higher inflammatory cytokine
load that might have influence on microglial activation and delirium days [37].
A recent meta-analysis of 12 randomized controlled trials including 2,380 patients by Bo
et al. analyzed the effect of GM-CSF on clinical outcome parameters in sepsis. GM-CSF was
demonstrated to significantly increase the reversal rate of infections in sepsis patients [38]. In
addition, Hall et al. found a significant reduction in secondary infectious complications in criti-
cally ill children under GM-CSF treatment [34]. However, until now no study has shown a
decreased rate of nosocomial infections in surgical patients at risk after treatment with
GM-CSF. In our study, the infection days after surgery were significantly lower under GM-CSF
treatment compared to placebo and vaccination group. Nevertheless, despite the fact that the
infection days were decreased up to day 9 after surgery, the total number of infections did not
differ between groups. These data suggest that GM-CSF treatment may mitigate the severity
and duration but may not prevent the development of post-operative infectious episodes. How-
ever, given that GM-CSF best protected patients from infections up to day 5 after surgery,
Table 4. Post-interventional course and outcome parameters. Continuous quantities in median (25%-75% percentiles), frequencies with n; APACHE,
Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TISS, Therapeu-
tic Intervention Scoring System; ICU, Intensive Care Unit.
Placebo (n = 20) Vaccine (n = 21) GM-CSF (n = 20) p-value (all groups)
SOFA score (max.) 3.5 (0.3–6.0) 2.0 (0.0–4.5) 4.0 (1.0–7.0) 0.414
TISS 28 score (max.) 34.5 (31.0–40.0) 33.0 (25.0–40.0) 36.0 (31.0–39.5) 0.788
ICU stay (d) 3.9 (2.3–4.9) 4.4 (0.8–21.3) 1.9 (0.8–5.0) 0.327
Hospital stay (d) 15.4 (12.3–22.2) 15.0 (13.0–31.5) 15.2 (11.2–25.3) 0.553
doi:10.1371/journal.pone.0144003.t004
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short-term immunostimulatory treatment may not be sufficient. In addition, mortality and
comorbidity endpoints other than infection were not influenced by GM-CSF. However, the
current study was not powered to assess these endpoints. Thus, additional studies are needed
to determine the most effective duration of immunostimulatory treatment regimens and
appropriate biomarker signatures indicative for sustained recovery of immune function and
improved clinical outcome.
Another finding of our study is that vaccination increased the number of delirium days. The
number of delirium days is positively associated with increased 1-year mortality [39, 40]. To
the best of our knowledge, there is currently no study that describes a risk for delirium after
influenza vaccination at all [41–43] aside from one case report [44]. However, the pathogenesis
of delirium is still not clearly understood. Some studies suggest that systemic inflammation
may affect cholinergic and immune system are of major relevance in the development of delir-
ium [45–47]. Hingorani et al. [48] and Clapp et al. [49] showed that vaccination leads to a sys-
temic inflammatory response which is associated with endothelial dysfunction. However, they
used salmonella typhi vaccination. Thus, we hypothesize that in our study influenza vaccina-
tion most likely induced a systemic inflammation which increased the risk of delirium perhaps
due to disruption of the blood-brain barrier [37, 50, 51]. Influenza vaccination may have nega-
tive effects on delirium that might be related to unspecific inflammatory stimulation and
should be investigated in further studies.
This study has several limitations. First, study drugs were administered only for a maximum
of 3 days. The effect of longer duration of therapy is unclear. Second, we observed small differ-
ences in univariate analyses for gender between the groups, but this was only descriptive
because multivariate analysis is not considered appropriate in that setting and would not show
any difference. Third, the threshold level for mHLA-DR ( 10,000 mAb/cell) used to select
patients with severe surgery-induced immunosuppression for immunostimulatory therapy in
this study is unclear. Previous studies have suggested using a mHLA-DR threshold between
5,000 and 10,000 mAb/cell as an indicator of severely impaired immune function in critical ill
patients [12, 24, 52]. However, it is currently unclear whether single cut-off values for
mHLA-DR can be applied to identify best patients at risk with different entities of trauma-asso-
ciated immunosuppression. It was recently demonstrated that mHLA-DR levels of< 20,000
mAb/cell were associated with the development of pneumonia in patients with severe stroke
[53]. Thus, further studies are needed to determine outcome-relevant thresholds for biomark-
ers of immune competence in order to optimize the risk-benefit profile of immunostimulatory
therapeutic approaches to overcome severe immunosuppression in critical illness. Fourth, the
use of influenza vaccine might have been insufficient to treat the HLA-DR response despite the
fact that proinflammatory stimulation might have increased delirium. A potential improve-
ment would be to use a vaccine known to increase HLA-DR response such as vaccination
against hepatitis B [54]. Finally, we observed patients for 9 days after surgery for infections.
Infections occurring after this time were not prospectively documented and could not be evalu-
ated. Furthermore, in this study we included patients after pancreatic and esophageal resection.
Conclusions
Postoperative application of GM-CSF significantly increased HLA-DR expression on mono-
cytes and decreased the duration of infection after surgery in patients undergoing esophageal
or pancreatic surgery. Postoperative influenza vaccination had no influence on post-surgical
immunosuppression but increased the number of delirium days. Further studies are warranted
to evaluate the benefit of immunostimulatory therapy with GM-CSF to improve clinical out-
come. The negative effects of influenza vaccination on cognition should be investigated as well.
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